The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
 
Debashis Sarker
Honoraria - Bayer; Ipsen; Pfizer; Pfizer (I)
Consulting or Advisory Role - Eisai; Eisai (I); Ipsen (I); Novartis; Surface Oncology
Speakers' Bureau - MSD Oncology
Travel, Accommodations, Expenses - Bayer; Eisai; ipsen; MiNA Therapeutics
 
Mikael Sodergren
Research Funding - MiNA Therapeutics
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; Novartis; Octimet; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Bristi Basu
Consulting or Advisory Role - Eisai (Inst); Genmab (Inst); Roche (Inst)
Speakers' Bureau - Eisai
Research Funding - Celgene (Inst); Genmab (Inst)
Travel, Accommodations, Expenses - Bayer
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Kai-Wen Huang
Research Funding - MiNA Therapeutics
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sierra Pharma (Inst); Starpharma (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Duncan Spalding
No Relationships to Disclose
 
Yuk Ting Ma
No Relationships to Disclose
 
Daniel H. Palmer
No Relationships to Disclose
 
Cheng Ean Chee
Consulting or Advisory Role - Bayer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Taiho Pharmaceutical
 
David James Pinato
Consulting or Advisory Role - Eisai; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb; MSD Oncology
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb
 
Vikash Reebye
Employment - MiNA Therapeutics
Stock and Other Ownership Interests - MiNA Therapeutics
 
Daniel McVeigh
Employment - MiNA Therapeutics
 
Nina Raulf
Employment - MiNA Therapeutics
 
Jenni Vasara
Employment - MiNA Therapeutics
 
Pinelopi Andrikakou
Research Funding - MiNA Therapeutics
 
Robert Habib
Employment - MiNA Therapeutics
Stock and Other Ownership Interests - MiNA Therapeutics
 
David Blakey
Employment - MiNA Therapeutics
Stock and Other Ownership Interests - MiNA Therapeutics
 
Nagy A. Habib
Employment - MiNA Therapeutics (I)
Stock and Other Ownership Interests - MiNA Therapeutics
Research Funding - MiNA Therapeutics